This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07184086 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 1 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 80 participants |
| Design | Interventional, Randomized, Parallel, Masking: None |
| Conditions | Obesity |
| Interventions | CagriSema (Cagrilintide B + semaglutide I); Low Energy Diet |
| Start | Sep 26, 2025 |
| Primary completion | Oct 12, 2027 |
| Study completion | Feb 9, 2028 |
| Results posted | Not yet |
| Registry last updated | Sep 10, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been tested in humans. The study is split into 2 parts. In the first part of the study, participants will either get CagriSema or a weight loss diet (calorie reduced). In the second part of the study,all participants will get CagriSema. Which treatment participants get in the first part of the study is decided by chance. Like all medicines, the study medicine may have side effects. The study will last for about 1.5 years.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change in sleeping metabolic rate (SMR) | Baseline (Week 0) to Week 20 |
3 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
